Table 3.
Comparison of treatment groups (lanthanum versus placebo) at week 96 for intermediate cardiovascular parameters and biochemical parameters
| Outcome Variable | N | Mean (SEM) at 96 Wk (lanthanum, placebo) | Difference (95% CI)a | P Value |
|---|---|---|---|---|
| PWV (m/s)b | 248 | 11.8 (0.33), 11.2 (0.33) | +0.6 (−0.3 to 1.5) | 0.20 |
| Serum phosphate (mmol/L) | 262 | 1.34 (0.03), 1.37 (0.03) | −0.03 (−0.12 to 0.05) | 0.40 |
| Serum calcium (mmol/L) | 261 | 2.31 (0.01), 2.29 (0.01) | +0.02 (−0.01 to 0.06) | 0.14 |
| Serum calcium-phosphate product (mmol2/L2) | 261 | 3.07 (0.07), 3.13 (0.07) | −0.06 (−0.24 to 0.13) | 0.54 |
| PTH (pmol/L)c | 226 | 2.76 (0.06), 2.75 (0.06) | +0.009 (−0.16 to 0.18) | 0.92 |
| cFGF23 (RU/ml)c | 226 | 5.82 (0.07), 5.85 (0.07) | −0.03 (−0.24 to 0.18) | 0.78 |
| iFGF23 (pg/ml)c | 237 | 5.28 (0.09), 5.35 (0.09) | −0.08 (−0.32 to 0.17) | 0.53 |
| cFGF23/iFGF23 ratioc | 221 | 0.69 (0.5), 0.73 (0.05) | −0.04 (−0.12 to 0.20) | 0.65 |
| Urinary phosphate excretion (mmol/24 h) | 236 | 22.01 (1.10), 23.17 (1.07) | −1.16 (−4.21 to 1.88) | 0.45 |
| Urine phosphate-creatinine ratio (mg/mmol) | 231 | 192.24 (8.86), 195.06 (8.61) | −2.82 (−27.20 to 21.56) | 0.82 |
| eGFR (ml/min/1.73 m2) | 262 | 21.5 (0.6), 22.2 (0.6) | −0.70 (−2.42 to 1.01) | 0.42 |
| Creatinine clearance (ml/min) | 233 | 30.09 (5.50), 40.63 (5.45) | −10.54 (−25.82 to 4.73) | 0.18 |
| Agatston score | 203 | 4147 (134), 3975 (133) | +172 (−200 to 545) | 0.36 |
Variables in the models include treatment group, visit, treatment group by visit interaction, and baseline variable. cFGF23, C-terminal FGF23; iFGF23, intact FGF23.
a
Lanthanum relative to placebo.
b
A total of 14 participants had imputed values for missing baseline PWV, and 30 participants had no follow-up data and were excluded.
c
Log transformed.